IMRX Insider Trading Activity and SEC Form 4 Filings
IMRX insider trading summary
Over the past 12 months, insiders at Immuneering Corp (IMRX) reported 7 open-market purchases worth $270K by 6 insiders and no sales on SEC Form 4. Net insider buying was $270K.
Latest IMRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jun 23, 2026 | Benjamin J. Zeskind | President and CEO | Buy | $11K (2,400 @ $4.56) |
| Jun 15, 2026 | Brett Matthew Hall | Chief Scientific Officer | Buy | $25K (6,035 @ $4.15) |
| Jan 16, 2026 | Harold Eugene Brakewood | Chief Business Officer | Buy | $25K (5,250 @ $4.76) |
| Jan 15, 2026 | Thomas J. Schall | Director | Buy | $101K (21,645 @ $4.67) |
| Jan 15, 2026 | Brett Matthew Hall | Chief Scientific Officer | Buy | $11K (2,298 @ $4.57) |
| Jan 13, 2026 | Leah R Neufeld | Chief People Officer | Buy | $11K (2,626 @ $4.15) |
| Jan 12, 2026 | Peter Feinberg | Director | Buy | $87K (20,000 @ $4.35) |
| Oct 3, 2025 | Peter Feinberg | Director | Buy | $50K (7,500 @ $6.67) |
| Oct 1, 2025 | Michael Bookman | Chief Legal Officer, Secretary | Buy | $7K (1,020 @ $6.83) |
| Oct 1, 2025 | Mallory Morales | Chief Accounting Officer | Buy | $2K (300 @ $6.39) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.